In 2025, the bronchiectasis market across seven major regions—the United States, the UK, Japan, and the EU4—reached an estimated USD 1.6 billion. The United States currently holds the largest share of this treatment landscape, which serves nearly 1 million patients diagnosed with non-cystic fibrosis bronchiectasis (NCFB). While standard care has historically relied on off-label bronchodilators and antibiotics to manage symptoms, the shift toward precision medicine is reshaping the clinical approach.
Bronchiectasis Market Forecasted to Reach 15% Annual Growth by 2036
The global bronchiectasis treatment market is entering a period of rapid expansion, with projections indicating a 15% compound annual growth rate through 2036. This surge is fueled by the emergence of targeted therapies, including DPP1 inhibitors and novel phage cocktails, designed to address the disease’s complex underlying inflammatory mechanisms.
A pivotal moment for the sector arrived with the approval of BRINSUPRI (brensocatib), the first FDA-authorized targeted therapy for NCFB. This regulatory success paves the way for a robust pipeline of experimental candidates. Leading firms such as Boehringer Ingelheim, Armata Pharmaceuticals, and Renovion are advancing treatments like Verducatib, AP-PA02, and ARINA-1. These therapies aim to move beyond simple symptom management by directly targeting neutrophil-driven inflammation and bacterial colonization, potentially transforming patient outcomes by 2036.
Comments (0)
No comments yet. Be the first!